United States Biotechnology & Medical Research

Fulcrum Therapeutics Inc (FULC)

Track

Track

Over the past 90 days, Fulcrum Therapeutics Inc. saw significant insider buying activity, totaling approximately $1.49 million, primarily driven by Kevin Tang. This contrasts with $130,593 in reported sales. The stock has experienced a 46.2% decline over the last 90 days, following a recent earnings report that missed expectations by 36.48%.
Ticker: FULC Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Fulcrum Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.3
TANG KEVIN Large shareholder
Transaction date
Purchase
Price
437.47
Quantity 12,756 +5.0%
Value US$483,149
3.3
TANG KEVIN Large shareholder
Transaction date
Purchase
Price
209.58
Quantity 91,014 +17.7%
Value US$4,225,200
3.3
TANG KEVIN Large shareholder
Transaction date
Purchase
Price
134.48
Quantity 32,625 +14.5%
Value US$1,712,808
3.3
TANG KEVIN Large shareholder
Transaction date
Purchase
Price
3.58
Quantity 75,952 +1.1%
Value US$271,908
3.3
TANG KEVIN Large shareholder
Transaction date
Purchase
Price
3.56
Quantity 53,651 +0.8%
Value US$190,998
3.3
TANG KEVIN Large shareholder
Transaction date
Purchase
Price
3.54
Quantity 12,966 +0.2%
Value US$45,900
2.8
Ezekowitz Alan Non-Executive Director
Transaction date
Planned sale
Price
3.65
Quantity 18,000 -62.2%
Value US$65,614
2.8
ALAN EZEKOWITZ Director Non-Executive Director
Transaction date
Proposed sale
Price
3.61
Quantity 18,000
Value US$64,980
Gould Robert J Non-Executive Director
Transaction date
Planned sale
Price
10.72
Quantity 15,000 -3.2%
Value US$160,857
Gould Robert J Non-Executive Director
Transaction date
Planned sale
Price
11.87
Quantity 15,000 -3.1%
Value US$178,089
2.5
Oltmans Curtis Gale Chief Legal Officer Officer
Transaction date
Planned sale
Price
12.92
Quantity 3,452 -25.2%
Value US$44,600
2.5
CURTIS G OLTMANS Officer Officer
Transaction date
Proposed sale
Price
13.00
Quantity 3,452
Value US$44,876
RA Capital Healthcare Fund LP 10% Stockholder Large shareholder
Transaction date
Proposed sale
Price
12.99
Quantity 4,175,139
Value US$54,235,056
Gould Robert J Non-Executive Director
Transaction date
Planned sale
Price
11.03
Quantity 15,000 -3.0%
Value US$165,495
ROBERT J GOULD Director Non-Executive Director
Transaction date
Proposed sale
Price
9.73
Quantity 45,000
Value US$437,850
1.4
Tourangeau Greg Principal Accounting Officer Officer
Transaction date
Planned sale
Price
5.06
Quantity 498 -3.4%
Value US$2,520
1.4
Tourangeau Greg Principal Accounting Officer Officer
Transaction date
Sale
Price
7.76
Quantity 236 -2.0%
Value US$1,831
1.4
Greg Tourangeau Officer Officer
Transaction date
Proposed sale
Price
11.72
Quantity 4,884
Value US$57,218
1.4
Tourangeau Greg Vice President, Finance Officer
Transaction date
Planned sale
Price
11.72
Quantity 4,884 -29.3%
Value US$57,219
0.5
Sapir Alex See Remarks Executive Director
Transaction date
Purchase
Price
11.35
Quantity 43,360 +inf%
Value US$492,028
1.4
Tourangeau Greg Principal Accounting Officer Officer
Transaction date
Sale
Price
3.31
Quantity 210 -1.3%
Value US$695
Gould Robert J Interim President & CEO Executive Director
Transaction date
Planned sale
Price
15.00
Quantity 6,766 -1.3%
Value US$101,490
Gould Robert J Non-Executive Director
Transaction date
Planned sale
Price
8.09
Quantity 71,435 -12.4%
Value US$577,895
Gould Robert J Non-Executive Director
Transaction date
Planned sale
Price
8.10
Quantity 24,382 -4.6%
Value US$197,592
Gould Robert J Non-Executive Director
Transaction date
Planned sale
Price
7.95
Quantity 25,551 -4.8%
Value US$203,056
Gould Robert J Non-Executive Director
Transaction date
Planned sale
Price
7.92
Quantity 16,689 -3.2%
Value US$132,162
Gould Robert J Non-Executive Director
Transaction date
Planned sale
Price
24.02
Quantity 5,631 -1.1%
Value US$135,228
Gould Robert J Non-Executive Director
Transaction date
Planned sale
Price
24.26
Quantity 52,552 -9.4%
Value US$1,274,775
Gould Robert J Non-Executive Director
Transaction date
Planned sale
Price
24.02
Quantity 7,235 -1.4%
Value US$173,749
Gould Robert J Non-Executive Director
Transaction date
Planned sale
Price
24.03
Quantity 34,464 -6.4%
Value US$828,160
Stuart Bryan See Remarks Executive Director
Transaction date
Planned sale
Price
23.75
Quantity 28,000 -100.0%
Value US$665,000
Stuart Bryan See Remarks Executive Director
Transaction date
Planned sale
Price
17.50
Quantity 32,000 -100.0%
Value US$560,000
2.5
Oltmans Curtis Gale SVP, General Counsel Officer
Transaction date
Purchase
Price
9.01
Quantity 1,088 +inf%
Value US$9,803
2.5
Thomson Peter G. VP Finance & Accounting Officer
Transaction date
Purchase
Price
9.00
Quantity 2,300 +inf%
Value US$20,700
2.4
Morabito Christopher Chief Medical Officer Officer
Transaction date
Purchase
Price
9.16
Quantity 1,100 +inf%
Value US$10,076
2.4
GERAGHTY JAMES A Non-Executive Director
Transaction date
Purchase
Price
9.16
Quantity 10,000 +12.4%
Value US$91,600
Gould Robert J See Remarks Executive Director
Transaction date
Planned sale
Price
12.43
Quantity 789 -0.2%
Value US$9,806
Gould Robert J See Remarks Executive Director
Transaction date
Planned sale
Price
12.13
Quantity 9,211 -1.8%
Value US$111,773
2.5
Thomson Peter G. VP Finance & Accounting Officer
Transaction date
Planned sale
Price
14.72
Quantity 5,000 -24.7%
Value US$73,582
Gould Robert J See Remarks Executive Director
Transaction date
Planned sale
Price
14.56
Quantity 1,673 -0.3%
Value US$24,367
Gould Robert J See Remarks Executive Director
Transaction date
Planned sale
Price
14.19
Quantity 6,542 -1.2%
Value US$92,830
2.5
Thomson Peter G. VP Finance & Accounting Officer
Transaction date
Planned sale
Price
14.00
Quantity 6,607 -30.3%
Value US$92,498
Gould Robert J See Remarks Executive Director
Transaction date
Planned sale
Price
12.08
Quantity 10,000 -1.9%
Value US$120,826
Wallace Owen B. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
20.00
Quantity 2,951 -2.3%
Value US$59,020
Gould Robert J See Remarks Executive Director
Transaction date
Planned sale
Price
20.00
Quantity 2,500 -0.5%
Value US$50,000
Cadavid Diego SVP Clinical Development Officer
Transaction date
Planned sale
Price
18.30
Quantity 1,071 -1.6%
Value US$19,599
Wallace Owen B. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
20.00
Quantity 141 -0.1%
Value US$2,820
Cadavid Diego SVP Clinical Development Officer
Transaction date
Planned sale
Price
22.00
Quantity 1,459 -2.1%
Value US$32,098
Gould Robert J See Remarks Executive Director
Transaction date
Planned sale
Price
20.80
Quantity 2,500 -0.5%
Value US$51,992
Cadavid Diego SVP Clinical Development Officer
Transaction date
Planned sale
Price
22.00
Quantity 401 -0.6%
Value US$8,822
Gould Robert J See Remarks Executive Director
Transaction date
Planned sale
Price
20.00
Quantity 156 -0.0%
Value US$3,120
Gould Robert J See Remarks Executive Director
Transaction date
Planned sale
Price
20.17
Quantity 3,433 -0.6%
Value US$69,251
Cadavid Diego SVP Clinical Development Officer
Transaction date
Planned sale
Price
20.18
Quantity 451 -0.7%
Value US$9,101
Cadavid Diego SVP Clinical Development Officer
Transaction date
Planned sale
Price
20.05
Quantity 226 -0.3%
Value US$4,531
Gould Robert J See Remarks Executive Director
Transaction date
Planned sale
Price
20.04
Quantity 1,300 -0.2%
Value US$26,058
Gould Robert J See Remarks Executive Director
Transaction date
Planned sale
Price
20.13
Quantity 1,500 -0.3%
Value US$30,192
Cadavid Diego SVP Clinical Development Officer
Transaction date
Planned sale
Price
20.18
Quantity 338 -0.5%
Value US$6,820
Cadavid Diego SVP Clinical Development Officer
Transaction date
Planned sale
Price
20.00
Quantity 45 -0.1%
Value US$900
Gould Robert J See Remarks Executive Director
Transaction date
Planned sale
Price
20.00
Quantity 2,797 -0.5%
Value US$55,940
Gould Robert J See Remarks Executive Director
Transaction date
Planned sale
Price
20.00
Quantity 5 -0.0%
Value US$100
Cadavid Diego SVP Clinical Development Officer
Transaction date
Planned sale
Price
20.04
Quantity 200 -0.3%
Value US$4,007
Gould Robert J See Remarks Executive Director
Transaction date
Planned sale
Price
20.08
Quantity 1,390 -0.3%
Value US$27,911
Cadavid Diego SVP Clinical Development Officer
Transaction date
Planned sale
Price
20.00
Quantity 600 -0.9%
Value US$12,000
Wallace Owen B. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
20.00
Quantity 2,232 -1.7%
Value US$44,640
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-20 2026-07-17 B Purchase
3.3
TANG KEVIN
Large shareholder
12,756 +5.0%
437.47
US$483,149 		12,756 +5.0% 437.47 US$483,149
2026-07-20 2026-07-16 B Purchase
3.3
TANG KEVIN
Large shareholder
91,014 +17.7%
209.58
US$4,225,200 		91,014 +17.7% 209.58 US$4,225,200
2026-07-15 2026-07-15 B Purchase
3.3
TANG KEVIN
Large shareholder
32,625 +14.5%
134.48
US$1,712,808 		32,625 +14.5% 134.48 US$1,712,808
2026-07-15 2026-07-14 B Purchase
3.3
TANG KEVIN
Large shareholder
75,952 +1.1%
3.58
US$271,908 		75,952 +1.1% 3.58 US$271,908
2026-07-15 2026-07-14 B Purchase
3.3
TANG KEVIN
Large shareholder
53,651 +0.8%
3.56
US$190,998 		53,651 +0.8% 3.56 US$190,998
2026-07-15 2026-07-13 B Purchase
3.3
TANG KEVIN
Large shareholder
12,966 +0.2%
3.54
US$45,900 		12,966 +0.2% 3.54 US$45,900
2026-06-30 2026-06-26 PlS Planned sale
2.8
Ezekowitz Alan
Non-Executive Director
18,000 -62.2%
3.65
US$65,614 		18,000 -62.2% 3.65 US$65,614
2026-06-26 2026-06-26 PrS Proposed sale
2.8
ALAN EZEKOWITZ

Director

Non-Executive Director
18,000
3.61
US$64,980 		18,000 3.61 US$64,980
2026-02-04 2026-02-02 PlS Planned sale
Gould Robert J
Non-Executive Director
15,000 -3.2%
10.72
US$160,857 		15,000 -3.2% 10.72 US$160,857
2026-01-06 2026-01-02 PlS Planned sale
Gould Robert J
Non-Executive Director
15,000 -3.1%
11.87
US$178,089 		15,000 -3.1% 11.87 US$178,089
2025-12-17 2025-12-15 PlS Planned sale
2.5
Oltmans Curtis Gale

Chief Legal Officer

Officer
3,452 -25.2%
12.92
US$44,600 		3,452 -25.2% 12.92 US$44,600
2025-12-15 2025-12-15 PrS Proposed sale
2.5
CURTIS G OLTMANS

Officer

Officer
3,452
13.00
US$44,876 		3,452 13.00 US$44,876
2025-12-10 2025-12-08 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
91,722 -1.5%
14.98
US$1,373,996 		91,722 -1.5% 14.98 US$1,373,996
2025-12-10 2025-12-08 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
2,706,397 -30.6%
14.28
US$38,647,349 		2,706,397 -30.6% 14.28 US$38,647,349
2025-12-10 2025-12-08 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
1,377,020 -13.5%
13.33
US$18,355,677 		1,377,020 -13.5% 13.33 US$18,355,677
2025-12-08 2025-12-08 PrS Proposed sale
RA Capital Healthcare Fund LP

10% Stockholder

Large shareholder
4,175,139
12.99
US$54,235,056 		4,175,139 12.99 US$54,235,056
2025-11-21 2025-11-19 PlS Planned sale
Gould Robert J
Non-Executive Director
15,000 -3.0%
11.03
US$165,495 		15,000 -3.0% 11.03 US$165,495
2025-11-19 2025-11-19 PrS Proposed sale
ROBERT J GOULD

Director

Non-Executive Director
45,000
9.73
US$437,850 		45,000 9.73 US$437,850
2025-05-09 2025-05-08 PlS Planned sale
1.4
Tourangeau Greg

Principal Accounting Officer

Officer
498 -3.4%
5.06
US$2,520 		498 -3.4% 5.06 US$2,520
2024-05-09 2024-05-07 S Sale
1.4
Tourangeau Greg

Principal Accounting Officer

Officer
236 -2.0%
7.76
US$1,831 		236 -2.0% 7.76 US$1,831
2024-03-08 2024-03-08 PrS Proposed sale
1.4
Greg Tourangeau

Officer

Officer
4,884
11.72
US$57,218 		4,884 11.72 US$57,218
2024-03-08 2024-03-08 PlS Planned sale
1.4
Tourangeau Greg

Vice President, Finance

Officer
4,884 -29.3%
11.72
US$57,219 		4,884 -29.3% 11.72 US$57,219
2024-03-05 2024-03-04 B Purchase
0.5
Sapir Alex

See Remarks

Executive Director
43,360 +inf%
11.35
US$492,028 		43,360 +inf% 11.35 US$492,028
2023-05-11 2023-05-10 S Sale
1.4
Tourangeau Greg

Principal Accounting Officer

Officer
210 -1.3%
3.31
US$695 		210 -1.3% 3.31 US$695
2023-01-24 2023-01-20 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
1,923,076 +19.9%
13.00
US$24,999,988 		1,923,076 +19.9% 13.00 US$24,999,988
2023-01-13 2023-01-13 PlS Planned sale
Gould Robert J

Interim President & CEO

Executive Director
6,766 -1.3%
15.00
US$101,490 		6,766 -1.3% 15.00 US$101,490
2023-01-06 2023-01-04 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
58,369 +0.6%
7.80
US$455,091 		58,369 +0.6% 7.80 US$455,091
2023-01-06 2023-01-04 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
122,334 +1.3%
7.03
US$859,714 		122,334 +1.3% 7.03 US$859,714
2022-12-29 2022-12-27 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
4,089 +0.0%
5.99
US$24,510 		4,089 +0.0% 5.99 US$24,510
2022-12-21 2022-12-19 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
98,787 +1.1%
5.90
US$582,814 		98,787 +1.1% 5.90 US$582,814
2022-12-16 2022-12-16 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
1,341,420 +16.6%
5.42
US$7,269,826 		1,341,420 +16.6% 5.42 US$7,269,826
2022-12-16 2022-12-15 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
237,029 +3.0%
5.50
US$1,302,474 		237,029 +3.0% 5.50 US$1,302,474
2022-12-16 2022-12-14 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
824,600 +11.8%
5.46
US$4,501,574 		824,600 +11.8% 5.46 US$4,501,574
2022-06-08 2022-06-07 PlS Planned sale
Gould Robert J
Non-Executive Director
71,435 -12.4%
8.09
US$577,895 		71,435 -12.4% 8.09 US$577,895
2022-06-06 2022-06-06 PlS Planned sale
Gould Robert J
Non-Executive Director
24,382 -4.6%
8.10
US$197,592 		24,382 -4.6% 8.10 US$197,592
2022-06-06 2022-06-03 PlS Planned sale
Gould Robert J
Non-Executive Director
25,551 -4.8%
7.95
US$203,056 		25,551 -4.8% 7.95 US$203,056
2022-06-06 2022-06-02 PlS Planned sale
Gould Robert J
Non-Executive Director
16,689 -3.2%
7.92
US$132,162 		16,689 -3.2% 7.92 US$132,162
2022-04-11 2022-04-07 PlS Planned sale
Gould Robert J
Non-Executive Director
5,631 -1.1%
24.02
US$135,228 		5,631 -1.1% 24.02 US$135,228
2022-04-05 2022-04-05 PlS Planned sale
Gould Robert J
Non-Executive Director
52,552 -9.4%
24.26
US$1,274,775 		52,552 -9.4% 24.26 US$1,274,775
2022-04-05 2022-04-04 PlS Planned sale
Gould Robert J
Non-Executive Director
7,235 -1.4%
24.02
US$173,749 		7,235 -1.4% 24.02 US$173,749
2022-04-05 2022-04-01 PlS Planned sale
Gould Robert J
Non-Executive Director
34,464 -6.4%
24.03
US$828,160 		34,464 -6.4% 24.03 US$828,160
2021-08-12 2021-08-11 PlS Planned sale
Stuart Bryan

See Remarks

Executive Director
28,000 -100.0%
23.75
US$665,000 		28,000 -100.0% 23.75 US$665,000
2021-08-12 2021-08-10 PlS Planned sale
Stuart Bryan

See Remarks

Executive Director
32,000 -100.0%
17.50
US$560,000 		32,000 -100.0% 17.50 US$560,000
2021-06-29 2021-06-28 B Purchase
2.5
Oltmans Curtis Gale

SVP, General Counsel

Officer
1,088 +inf%
9.01
US$9,803 		1,088 +inf% 9.01 US$9,803
2021-06-29 2021-06-28 B Purchase
2.5
Thomson Peter G.

VP Finance & Accounting

Officer
2,300 +inf%
9.00
US$20,700 		2,300 +inf% 9.00 US$20,700
2021-06-29 2021-06-28 B Purchase
2.4
Morabito Christopher

Chief Medical Officer

Officer
1,100 +inf%
9.16
US$10,076 		1,100 +inf% 9.16 US$10,076
2021-06-29 2021-06-28 B Purchase
2.4
GERAGHTY JAMES A
Non-Executive Director
10,000 +12.4%
9.16
US$91,600 		10,000 +12.4% 9.16 US$91,600
2021-03-17 2021-03-16 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
789 -0.2%
12.43
US$9,806 		789 -0.2% 12.43 US$9,806
2021-03-17 2021-03-15 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
9,211 -1.8%
12.13
US$111,773 		9,211 -1.8% 12.13 US$111,773
2021-02-24 2021-02-22 PlS Planned sale
2.5
Thomson Peter G.

VP Finance & Accounting

Officer
5,000 -24.7%
14.72
US$73,582 		5,000 -24.7% 14.72 US$73,582
2021-02-18 2021-02-16 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
1,673 -0.3%
14.56
US$24,367 		1,673 -0.3% 14.56 US$24,367
2021-02-18 2021-02-16 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
6,542 -1.2%
14.19
US$92,830 		6,542 -1.2% 14.19 US$92,830
2021-01-25 2021-01-21 PlS Planned sale
2.5
Thomson Peter G.

VP Finance & Accounting

Officer
6,607 -30.3%
14.00
US$92,498 		6,607 -30.3% 14.00 US$92,498
2021-01-22 2021-01-20 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
10,000 -1.9%
12.08
US$120,826 		10,000 -1.9% 12.08 US$120,826
2020-07-09 2020-07-08 PlS Planned sale
Wallace Owen B.

Chief Scientific Officer

Officer
2,951 -2.3%
20.00
US$59,020 		2,951 -2.3% 20.00 US$59,020
2020-07-09 2020-07-08 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
2,500 -0.5%
20.00
US$50,000 		2,500 -0.5% 20.00 US$50,000
2020-07-02 2020-07-01 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
1,071 -1.6%
18.30
US$19,599 		1,071 -1.6% 18.30 US$19,599
2020-07-01 2020-06-30 PlS Planned sale
Wallace Owen B.

Chief Scientific Officer

Officer
141 -0.1%
20.00
US$2,820 		141 -0.1% 20.00 US$2,820
2020-06-26 2020-06-25 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
1,459 -2.1%
22.00
US$32,098 		1,459 -2.1% 22.00 US$32,098
2020-06-26 2020-06-25 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
2,500 -0.5%
20.80
US$51,992 		2,500 -0.5% 20.80 US$51,992
2020-06-12 2020-06-10 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
401 -0.6%
22.00
US$8,822 		401 -0.6% 22.00 US$8,822
2020-06-10 2020-06-09 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
156 -0.0%
20.00
US$3,120 		156 -0.0% 20.00 US$3,120
2020-06-09 2020-06-05 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
3,433 -0.6%
20.17
US$69,251 		3,433 -0.6% 20.17 US$69,251
2020-06-08 2020-06-05 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
451 -0.7%
20.18
US$9,101 		451 -0.7% 20.18 US$9,101
2020-06-08 2020-06-04 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
226 -0.3%
20.05
US$4,531 		226 -0.3% 20.05 US$4,531
2020-06-05 2020-06-04 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
1,300 -0.2%
20.04
US$26,058 		1,300 -0.2% 20.04 US$26,058
2020-06-05 2020-06-03 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
1,500 -0.3%
20.13
US$30,192 		1,500 -0.3% 20.13 US$30,192
2020-06-04 2020-06-03 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
338 -0.5%
20.18
US$6,820 		338 -0.5% 20.18 US$6,820
2020-06-04 2020-06-02 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
45 -0.1%
20.00
US$900 		45 -0.1% 20.00 US$900
2020-06-03 2020-06-02 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
2,797 -0.5%
20.00
US$55,940 		2,797 -0.5% 20.00 US$55,940
2020-06-03 2020-06-01 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
5 -0.0%
20.00
US$100 		5 -0.0% 20.00 US$100
2020-06-01 2020-05-29 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
200 -0.3%
20.04
US$4,007 		200 -0.3% 20.04 US$4,007
2020-06-01 2020-05-29 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
1,390 -0.3%
20.08
US$27,911 		1,390 -0.3% 20.08 US$27,911
2020-06-01 2020-05-28 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
600 -0.9%
20.00
US$12,000 		600 -0.9% 20.00 US$12,000
2020-06-01 2020-05-28 PlS Planned sale
Wallace Owen B.

Chief Scientific Officer

Officer
2,232 -1.7%
20.00
US$44,640 		2,232 -1.7% 20.00 US$44,640
Explore more

More insider trading research around Fulcrum Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America